(Q36870158)

16 August 2017

1 reference

title

Treatment goals in psoriasis (English)

1 reference

16 August 2017

Kristian Reich

1

1 reference

16 August 2017

Ulrich Mrowietz

series ordinal

2

1 reference

16 August 2017

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

566-574

1 reference

[S3-Guidelines for the therapy of psoriasis vulgaris].

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Introduction. The magnitude of skin disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Psoriasis and sex: a study of moderately to severely affected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Lipid profile, insulin secretion, and insulin sensitivity in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Current severe psoriasis and the rule of tens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06343.X

10.1111/J.1610-0387.2007.06343.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference